US HB7237

Requires chemical abortion providers receiving federal funds to provide patients with FDA-approved product labels for abortion-inducing drugs, with "Warnings and Precautions" and "Adverse Reactions" sections highlighted, at least 24 hours before the procedure

Mandates that providers read the highlighted warning sections aloud to the patient and obtain written confirmation that these disclosure requirements have been fulfilled

Authorizes the Secretary to withhold federal funding from non-compliant providers or their employing entities, with providers required to submit implementation plans within 30 days of enactment

Creates a private right of action allowing women or their parents to sue non-compliant providers for money damages, statutory damages equal to 3 times the abortion cost, punitive damages, and attorney's fees

Excludes from the definition of "chemical abortion" procedures to prevent maternal death or irreversible bodily harm, treatment of ectopic or molar pregnancies, and miscarriage treatment